Literature DB >> 30508536

Outcomes After Thoracic Endovascular Aortic Repair With Overstenting of the Left Subclavian Artery.

Maximilian Luehr1, Christian D Etz2, Mikolaj Berezowski3, Michael Nozdrzykowski2, Thomas Jerkku4, Sven Peterss5, Michael A Borger2, Martin Czerny3, Ramin Banafsche4, Maximilian A Pichlmaier5, Friedhelm Beyersdorf3, Christian Hagl5, Andrej Schmidt6, Bartosz Rylski3.   

Abstract

BACKGROUND: Our study aim was to evaluate the impact of left subclavian artery (LSA) flow preservation during thoracic endovascular aortic repair (TEVAR) on outcome.
METHODS: Between August 2001 and October 2016, 176 patients (mean age, 61.3 ± 15.8 years) underwent TEVAR with complete LSA coverage. Fifty-five of those patients (31.3%) also underwent LSA revascularization, whereas 121 patients (68.7%) did not. Perioperative data were acquired retrospectively for statistical analysis at the three study institutions.
RESULTS: Overall in-hospital and follow-up mortality was 8.5% (n = 15) and 9.1% (n = 16), respectively, including 88 urgent and emergent cases (50%). Stroke (independent of location) and permanent paraplegia rates were 6.8% and 6.3%, respectively, for the entire cohort. Isolated upper-left extremity malperfusion exclusively occurred in 12 (9.9%) of the 121 patients without LSA revascularization. Left-hemispheric stroke was observed four times more often in patients without LSA revascularization and left arm malperfusion (16.7% versus 3.7%, p = 0.095). Multivariate analysis identified no LSA revascularization (odds ratio [OR] 3.779, 95% confidence interval [CI]: 1.096 to 13.029, p = 0.035), two or more endografts (OR 3.814, 95% CI: 1.557 to 9.343, p = 0.003), and coronary artery disease (OR 3.276, 95% CI: 1.262 to 8.507, p = 0.015) as independent risk factors for procedure-related adverse events (left-hemispheric stroke, left arm malperfusion, and permanent paraplegia) after TEVAR with complete LSA overstenting.
CONCLUSIONS: Every 10th patient with LSA overstenting and no revascularization experienced left arm malperfusion. No LSA revascularization, extensive aortic coverage with two or more endografts, and coronary artery disease increased the risk of permanent paraplegia, left-hemispheric stroke, and left arm malperfusion. Patients should undergo LSA revascularization to prevent left vertebral artery-associated central neurologic complications and to maintain upper-left extremity perfusion.
Copyright © 2019 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30508536     DOI: 10.1016/j.athoracsur.2018.10.051

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

Review 1.  Narrative review on endovascular techniques for left subclavian artery revascularization during thoracic endovascular aortic repair and risk factors for postoperative stroke.

Authors:  Mario D'Oria; Kevin Mani; Randall DeMartino; Martin Czerny; Konstantinos P Donas; Anders Wanhainen; Sandro Lepidi
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-05-10

2.  Early and Mid-Term Outcomes of Open versus Endovascular Left Subclavian Artery Debranching for Thoracic Aortic Diseases.

Authors:  Philip Dueppers; Lorenz Meuli; Benedikt Reutersberg; Michael Hofmann; Florian Messmer; Alexander Zimmermann
Journal:  Ann Thorac Cardiovasc Surg       Date:  2021-12-22       Impact factor: 1.889

3.  Endovascular repair of a ruptured, extremely tortuous, descending thoracic aorta aneurysm with aortic coarctation.

Authors:  Marieke Hoogewerf; Martijn W A van Geldorp; Joep G F Scholten; Jan Albert Vos; Robin H Heijmen
Journal:  J Vasc Surg Cases Innov Tech       Date:  2022-07-31

4.  Physician-Modified TEVAR versus Hybrid Repair of the Proximal Descending Thoracic Aorta.

Authors:  Miroslav Dimitrov Yordanov; Alexander Oberhuber; Abdulhakim Ibrahim
Journal:  J Clin Med       Date:  2022-06-16       Impact factor: 4.964

Review 5.  Comprehensive review of hybrid aortic arch repair with focus on zone 0 TEVAR and our institutional experience.

Authors:  Saket Singh; Stevan S Pupovac; Roland Assi; Prashanth Vallabhajosyula
Journal:  Front Cardiovasc Med       Date:  2022-09-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.